N/A
N=2,211
Building Electronic Tools To Enhance and Reinforce CArdiovascular REcommendations - Heart Failure (BETTER CARE-HF)
Heart Failure · Heart Failure With Reduced Ejection Fraction
Bottom Line
View on ClinicalTrials.gov: NCT05275920 ↗Enrolled (actual)
2,211
Serious AEs
0.0%
Results posted
Oct 2024
Primary outcome: Primary: Number of Participants Prescribed Mineralocorticoid Receptor Antagonists (MRA) During Study — 224; 127; 75 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Best Practice Alert (BPA) (Other); In-Basket Message (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- NYU Langone Health
- Primary completion
- Oct 2022
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants Prescribed Mineralocorticoid Receptor Antagonists (MRA) During Study |
224; 127; 75 | — |
| SECONDARY Number of Participants Prescribed to Beta-blocker (BB), Angiotensin Converting Enzyme (ACE) Inhibitor, Angiotensin Receptor Blocker (ARB), or Angiotensin Receptor/Neprilysin Inhibitor (ARNI) During Study |
87; 94; 85 | — |
Summary
Building Electronic Tools To Enhance and Reinforce CArdiovascular REcommendations - Heart Failure (BETTER CARE-HF) is a pragmatic, cluster-randomized, three-arm intervention trial that will compare the effectiveness of two targeted clinical decision support (CDS) intervention tools (best practice alert (BPA) and automated in-basket massage) to inform providers when a patient with heart failure and reduce ejection fraction (HFrEF) is not on appropriate medical therapy, as compared to usual care.
Eligibility Criteria
Inclusion Criteria
- Cardiologist visit
- Transthoracic echocardiogram with the most recent EF >= 40%
Exclusion Criteria
- Hypotension: SBP 5.1, or any K >5.5
- Renal dysfunction: eGFR < 30
- Ventricular assist device
- Hospice care
- Cardiac amyloid
Data sourced from ClinicalTrials.gov (NCT05275920). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.